"Today, we are celebrating a breakthrough moment for people with diabetes in the U.S.—an end to the worry and hassles associated with routine finger sticks which have been the standard of glucose testing for more than 40 years," Jared Watkin, senior vice president of diabetes care at Abbott, said in a Sept.
"At Abbott, we believe that FreeStyle Libre will transform diabetes management and we're proud to be at the forefront of innovation that empowers people to take control of their health to live their best lives." In June 2016, Abbott announced the results of a six-month trial of 252 adults with type 1 diabetes.
Participants with the FreeStyle Libre system spent 38 percent less time in hypoglycemia than those using the traditional method of adding a drop of blood from the finger to a test strip.
"This clinical trial has proven that patients will test more often when they have an easier and more convenient way to do so utilizing a device like FreeStyle Libre, leading them to ultimately being healthier, which is our goal for our patients,” lead investigator Jan Bolinder, MD, of Karolinska Institutet in Stockholm, said in a press release announcing the trial results.
Now, it will be available to the approximately 30 million Americans who have diabetes.